After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal

Aimmune Therapeutics Inc. has gobbled up a $200 million investment from Swiss food and drink conglomerate Nestlé S.A. and licensed an experimental drug. The deals come after Brisbane-based Aimmune (NASDAQ: AIMT) surged then slipped after winning Food and Drug Administration approval Friday of the first drug, Palforzia, to prevent reactions to accidental exposures to peanuts. It was eight-year-old Aimmune's first drug approval, but analysts have questioned if its dosing regimen will dampen broad…

Click to view original post